TALi Health is delighted to announce that Dr Mary Beth Brinson has been appointed as the CEO of TALi Health.
Dr Brinson was appointed as Chief Medical Officer earlier this year, however due to her broad experience and business capabilities, we feel that Dr Brinson is the right person for the CEO role. We are pleased she has accepted, and her appointment is effective immediately.
“I am very pleased to accept the role of CEO at TALi Health. The opportunity to help children with chronic attention issues using digital therapeutics is an important one. I am looking forward to achieving this goal with TALi Health.” Dr Brinson commented.
Dr Brinson was former Vice President, Global Clinical Affairs, with medical devices leader Cochlear Limited (ASX: COH). She holds a Doctorate in Audiology from the University of Louisville in Kentucky, a Master of Business Administration from Rutgers University in New Jersey and a bachelor’s degree in Audiology and Speech Pathology from the University of Georgia in the United States.
Mary Beth has held several senior roles during a 16-year career at Cochlear including Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training. She is a qualified Audiologist and has practiced in healthcare and academia in the U.S. and United Kingdom. She is also an Adjunct Fellow at Macquarie University in Sydney. Her appointment in this new role takes effect 27th June 2022.